|
| 37217482 | Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. | Blood Cancer J | 2023 |
| 35195258 | Understanding Drug Sensitivity and Tackling Resistance in Cancer. | Cancer Res | 2022 |
| 35646666 | Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. | Front Oncol | 2022 |
| 35853457 | Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. | Cell Chem Biol | 2022 |
| 35264575 | secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. | Blood Cancer J | 2022 |
| 34137665 | Pharmacogenomics education, research and clinical implementation in the state of Minnesota. | Pharmacogenomics | 2021 |
| 32724061 | In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. | Blood Cancer J | 2020 |
| 30607001 | Molecular signatures of multiple myeloma progression through single cell RNA-Seq. | Blood Cancer J | 2019 |
| 31537791 | Discovering genetic interactions bridging pathways in genome-wide association studies. | Nat Commun | 2019 |
| 31111659 | Identification of a de novo FOXP1 mutation and incidental discovery of inherited genetic variants contributing to a case of autism spectrum disorder and epilepsy. | Mol Genet Genomic Med | 2019 |
| 30683909 | The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. | Leukemia | 2019 |
| 29774113 | EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. | Oncotarget | 2018 |
| 30008546 | Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. | J Law Med Ethics | 2018 |
| 27981867 | Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. | Leuk Lymphoma | 2017 |
| 28415782 | Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. | Oncotarget | 2017 |
| 29242603 | Development of expression-based biomarkers of Dasatinib response in hematologic malignancies. | Blood Cancer J | 2017 |
| 28665416 | A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. | Blood Cancer J | 2017 |
| 26001594 | Applications and limitations in translating genomics to clinical practice. | Transl Res | 2016 |
| 28361099 | A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors. | Mol Genet Genomic Med | 2016 |
| 26422532 | Risk of multiple myeloma in a case-spouse study. | Leuk Lymphoma | 2016 |
| 27239040 | PIAS1 Promotes Lymphomagenesis through MYC Upregulation. | Cell Rep | 2016 |
| 27242896 | Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate. | Front Genet | 2016 |
| 26710886 | Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. | Leukemia | 2016 |
| 26479555 | Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations. | J Law Med Ethics | 2015 |
| 26479561 | Returning a Research Participant's Genomic Results to Relatives: Perspectives from Managers of Two Distinct Research Biobanks. | J Law Med Ethics | 2015 |
| 23734619 | Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. | Leuk Lymphoma | 2014 |
| 25368671 | Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. | J Cancer | 2014 |
| 25005244 | High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. | Leukemia | 2014 |
| 23536725 | Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. | Mol Cancer Ther | 2013 |
| 24204892 | Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. | PLoS One | 2013 |
| 23728080 | Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. | Leukemia | 2013 |
| 22120021 | Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. | Exp Hematol | 2012 |
| 22536319 | High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions. | PLoS One | 2012 |
| 22436882 | Managing incidental findings and research results in genomic research involving biobanks and archived data sets. | Genet Med | 2012 |
| 22382801 | Mapping the inputs, analyses, and outputs of biobank research systems to identify sources of incidental findings and individual research results for potential return to participants. | Genet Med | 2012 |
| 22382800 | Return of individual research results and incidental findings in the clinical trials cooperative group setting. | Genet Med | 2012 |
| 20488540 | Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. | Leuk Res | 2011 |
| 21903769 | Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. | Clin Cancer Res | 2011 |
| 21245421 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. | J Clin Oncol | 2011 |
| 21532841 | Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk. | Int J Mol Epidemiol Genet | 2010 |
| 19798094 | International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. | Leukemia | 2009 |
| 19657367 | Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. | Leukemia | 2009 |
| 18547191 | Managing incidental findings in human subjects research: analysis and recommendations. | J Law Med Ethics | 2008 |
| 18778477 | Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. | BMC Med | 2008 |
| 18805967 | Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. | Blood | 2008 |
| 19017943 | Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. | J Immunol | 2008 |
| 18528420 | Clinical and biological significance of RAS mutations in multiple myeloma. | Leukemia | 2008 |
| 18547197 | Genomic research and incidental findings. | J Law Med Ethics | 2008 |
| 16840723 | Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. | Blood | 2007 |
| 17483317 | A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. | Cancer Res | 2007 |